# X-Therma > You have Time. --- ## Pages - [XT-Thrive Thank You](https://x-therma.com/products/xt-thrive/xt-thrive-thank-you/): Contact X-Therma – we'd love to hear from you! Fill out the contact form and we will reach out to you as soon as possible. - [Contact Thank You](https://x-therma.com/contact-thank-you/): Contact X-Therma – we'd love to hear from you! Fill out the contact form and we will reach out to you as soon as possible. - [XT-Vivo + TimeSeal](https://x-therma.com/products/xt-vivo-timeseal/): We're combating organ shortage with a breakthrough organ preservation solution that prevents ice from forming on organs, cells, and tissues. - [XT-Thrive Contact](https://x-therma.com/products/xt-thrive/xt-thrive-contact/): Contact X-Therma – we'd love to hear from you! Fill out the contact form and we will reach out to you as soon as possible. - [XT-Thrive](https://x-therma.com/products/xt-thrive/): Our platform enables safe and effective cryopreservation for all regenerative medicines without DMSO, serum or other unknown components. - [Home](https://x-therma.com/): At X-Therma, we're advancing regenerative medicine and organ transplantation with a novel biopreservation solution. - [Jobs](https://x-therma.com/career/jobs/): We believe in investing in people and building meaningful relationships People are the heart and soul of X-Therma. Without our... - [About](https://x-therma.com/company/about/): Removing Time from the Equation X-Therma enables the robust preservation of cells, tissues, organs, and other biologics by leveraging our... - [Imprint](https://x-therma.com/imprint/): Imprint X-Therma Inc. 2600 Hilltop Drive Suite B220 Richmond, CA 94806 X-Therma GmbH Kaiserjägerstraße 30 A-6020 Innsbruck FN 564408 m... - [Data Policy](https://x-therma.com/data-policy/): Privacy Policy 1. An overview of data protection General information The following information will provide you with an easy to... - [References](https://x-therma.com/references/): References Home Verheijen, M. et al. (2019) “DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro,”... - [X-Therma Team](https://x-therma.com/company/team/): X-Therma Team Excellence is spread out across the U.S. and Europe, hired for the expertise and attributes that they bring to the table. - [Why X-Therma?](https://x-therma.com/career/why-x-therma/): Win the race against time with us using cell and organ cryopreservation solutions that are changing regenerative medicine. - [Careers](https://x-therma.com/career/): Join X-Therma for a cutting-edge position in biotechnology as we unlock a way to eliminate organ transplant waiting lists worldwide. - [Company](https://x-therma.com/company/): X-Therma is helping reimagine biotime using ground-breaking cold chain technology to advance Regenerative Medicine. - [Science](https://x-therma.com/science/): Inspired by the behaviors of arctic fish, X-Therma has applied nanoscience to create advanced antifreeze proteins that prevent ice formation. - [XT-Vivo + TimeSeal old](https://x-therma.com/products/xt-vivo-timeseal-old/): We're combating organ shortage with a breakthrough organ preservation solution that prevents ice from forming on organs, cells, and tissues. - [XT-Thrive Old](https://x-therma.com/products/xt-thrive-old/): Our platform enables safe and effective cryopreservation for all regenerative medicines without DMSO, serum or other unknown components. - [Products](https://x-therma.com/products/): X-Therma's biopreservation platform enables long-term storage to win the race again time for transplants, and cell & gene therapy. - [News](https://x-therma.com/newsroom/): Get the latest X-Therma Inc. news about cryopreservation and biopreservation and the important work we're doing to eliminate organ storages. - [Thank You](https://x-therma.com/contact/thank-you/): Thank You Your time is valuable. A member of our team will be in touch within 24 hours to discuss... - [Resources](https://x-therma.com/resources/): Resources Looking for data, research backed studies, and helpful tips and recommendations from industry experts? You came to the right... - [Consent](https://x-therma.com/consent/): Consent Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.... - [Contact](https://x-therma.com/contact/): Contact X-Therma – we'd love to hear from you! Fill out the contact form and we will reach out to you as soon as possible. - [Old Home](https://x-therma.com/home-old/): At X-Therma, we're advancing regenerative medicine and organ transplantation with a novel biopreservation solution. --- ## Posts --- ## News - [X-Therma Showcases Groundbreaking Organ Preservation Technology at Johns Hopkins' "Hopkins on the Hill" Event](https://x-therma.com/news/x-therma-showcases-groundbreaking-organ-preservation-technology-at-johns-hopkins-hopkins-on-the-hill-event/): X-Therma proudly announces its participation in the prestigious Hopkins on the Hill event, held on June 11, 2025, in Washington,... - [X-Therma Welcomes Biotech Veteran Neil Warma to its Board of Directors](https://x-therma.com/news/x-therma-welcomes-biotech-veteran-neil-warma-to-its-board-of-directors/): X-Therma Inc., a pioneering biotechnology company focused on revolutionizing regenerative medicine through its innovative biopreservation platform, today announced the appointment of Neil Warma, a seasoned healthcare entrepreneur with over 25 years of experience in managing and advising numerous biotechnology and pharmaceutical companies globally, to its Board of Directors. This strategic addition comes as X-Therma continues to advance its mission of transforming “living” medicines into on-demand treatments, addressing critical needs in organ transplantation and the rapidly evolving field of cell and gene therapies. - [X-Therma Achieves World’s First Subzero Organ Transports: Multiple 48-Hour Transatlantic Journeys Support First Steps Toward Tackling Organ Waitlist](https://x-therma.com/news/x-therma-achieves-worlds-first-subzero-organ-transports-multiple-48-hour-transatlantic-journeys-support-first-steps-toward-tackling-organ-waitlist/): Surgeons successfully transported pig kidneys between Baltimore and Innsbruck five times using X-Therma's FDA Breakthrough-designated subzero preservation technology - [X-Therma Achieves GMP Commercial Readiness with XT-Thrive<sup>®</sup>](https://x-therma.com/news/x-therma-achieves-gmp-commercial-readiness-with-xt-thrive/): X-Therma Inc. , a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, has achieved GMP (Good... - [X-Therma Announces XT-Thrive<sup>®</sup> Drug Master File (DMF) Accepted by U.S. Food and Drug Administration (FDA)](https://x-therma.com/news/x-therma-announces-xt-thrive-drug-master-file-dmf-accepted-by-u-s-food-and-drug-administration-fda/): X-Therma Inc. , a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, announces that the Food... - [X-Therma's $22.4M Series B Sets Stage to Transform Regenerative Medicine and Organ Transplantation](https://x-therma.com/news/x-thermas-22-4m-series-b-sets-stage-to-transform-regenerative-medicine-and-organ-transplantation/): X-Therma Inc. , a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, has completed an oversubscribed... - [Preserve Mammalian Cells At Ultra-Low Temperatures With XT-Thrive®](https://x-therma.com/news/preserve-mammalian-cells-at-ultra-low-temperatures-with-xt-thrive/): XT-Thrive® is a DMSO-free, serum-free, protein-free, and chemically defined cryopreservation media for the preservation of mammalian cells at ultra-low temperatures... - [XT-ViVo® & TimeSeal® Multi-Day Preservation of Organs, Tissues And Cells](https://x-therma.com/news/xt-vivo-timeseal-multi-day-preservation-of-organs-tissues-and-cells/): Learn how XT-ViVo® & TimeSeal® will enable multi-day preservation and remove time from the equation. The global shortage of transplantable... - [Advancing Treatment For Type 1 Diabetes With Drs. Camillo Ricordi And Xiaoxi Wei](https://x-therma.com/news/advancing-treatment-for-type-1-diabetes-with-drs-camillo-ricordi-and-xiaoxi-wei/): Dr. Camillo Ricordi may be a familiar name to anyone who has, or has known someone, with type 1 diabetes.... - [The Future Of DMSO-Free And Serum-Free Cryopreservation For Advanced Therapies](https://x-therma.com/news/the-future-of-dmso-free-and-serum-free-cryopreservation-for-advancedtherapies/): Cryopreservation is a crucial part of bioprocessing and biopharmaceutical manufacturing, storage, and transport – by using very low temperatures top... - [Science Chops Alone Don’t Cut It: The Entrepreneurial Growth Struggle](https://x-therma.com/news/science-chops-alone-dont-cut-it-the-entrepreneurial-growth-struggle/): In the eight years since launching X-Therma, we’ve achieved chemistry breakthroughs that we believe will truly propel the field of... - [Next-Generation Cryopreservation Techniques: Improving Cold Chain Management For Regenerative Medicines](https://x-therma.com/news/next-generation-cryopreservation-techniques-improving-cold-chain-management-for-regenerative-medicines/): Cryopreservation has become a crucial component in realizing the large-scale commercial manufacturing of regenerative medicines, which require unique storage and... - [X-Therma FCOI Policy](https://x-therma.com/news/x-therma-fcoi-policy/): X-Therma posts our FCOI to meet requirements of our incoming NIH funding. You can read the policy here: XT_FCOI - [Next-Generation DMSO-Free & Serum-Free Cryopreservation For Cell And Gene Therapy Manufacturing And Processing](https://x-therma.com/news/next-generation-dmso-free-serum-free-cryopreservation-for-cell-and-gene-therapy-manufacturing-and-processing/): Listen in on this discussion about the latest developments in cryopreservation technologies and how they can revolutionize cell and gene... - [Fixing The Regenerative Medicine Supply Chain](https://x-therma.com/news/fixing-the-regenerative-medicine-supply-chain-2/): In the past few years, specifically through the COVID-19 pandemic, supply-chain vulnerabilities have become the topic of everyday conversation across... - [Next Generation Cryopreservation To Help Advance Cell And Gene Therapies](https://x-therma.com/news/next-generation-cryopreservation-to-help-advance-cell-and-gene-therapies/): The world has been waiting for the next scientific breakthrough incryopreservation. Dimethyl sulfoxide (DMSO), a by-product of the wood industry,... - [XT-Thrive and X-Therma: Next Generation cryopreservation to help advance Cell and Gene Therapies](https://x-therma.com/news/xt-thrive-and-x-therma-next-generation-cryopreservation-to-help-advance-cell-and-gene-therapies/): The world has been waiting for the next scientific breakthrough in cryopreservation. Dimethyl sulfoxide (DMSO), a by-product of the wood... - [X-Therma Completes NSF Program With Flying Colors](https://x-therma.com/news/x-therma-completes-nsf-program-with-flying-colors/): X-Therma is proud to announce an important milestone on our journey toward enabling more and better organ transplants and off-the-shelf... - [A Bioinspired And Chemically Defined Alternative To Dimethyl Sulfoxide For The Cryopreservation Of Human Hematopoietic Stem Cells](https://x-therma.com/news/a-bioinspired-and-chemically-defined-alternative-to-dimethyl-sulfoxide-for-the-cryopreservation-of-human-hematopoietic-stem-cells/): The cryopreservation of hematopoietic cells using dimethyl sulfoxide (DMSO) and serum is a common procedure used in transplantation. However, DMSO... - [Creating time: How emulating nature can help us improve outcomes for organ transplant patients](https://x-therma.com/news/creating-time-how-emulating-nature-can-help-us-improve-outcomes-for-organ-transplant-patients/): I have spent my life thinking about time. How to pause it. How to create more of it. How to... - [Taking The Toxins Out Of Cell Therapy Storage: A New Cryopreservation Molecule](https://x-therma.com/news/taking-the-toxins-out-of-cell-therapy-storage-a-new-cryopreservation-molecule/): Inspired by nature, a new type of cryoprotectant has emerged as a safer alternativeto traditional chemicals. The preservation of living... - [Novel Cryopreservation For Cell And Gene Therapies](https://x-therma.com/news/novel-cryopreservation-for-cell-and-gene-therapies/): The concept of cooling organic materials in order to slow their decay is as old as civilization itself. For the... - [Next-Generation DMSO-Free & Serum-Free Cryopreservation For Cell And Gene Therapy](https://x-therma.com/news/next-generation-dmso-free-serum-free-cryopreservation-for-cell-and-gene-therapy/): Existing standards in cryopreservation use 5-10% dimethyl sulfoxide (DMSO) andoften serum. These products have not been significantly improved for over... - [Chemically Defined, Safe And Effective Cryopreservation](https://x-therma.com/news/chemically-defined-safe-and-effective-cryopreservation/): XT-Thrive® contains fully synthetic biomimetics (peptoids) which are non-toxic, and prevent harmful ice crystal formation in cells at temperatures down... - [A Wonderful Celebration of Our Seventh Anniversary](https://x-therma.com/news/a-wonderful-celebration-of-our-seventh-anniversary/): What a wonderful celebration of the 7th anniversary we had on Halloween weekend! We truly appreciate the commitment and contribution... - [Reducing Adverse Events And Improving Outcomes During And After Cell and Gene Therapy With DMSO-Free, Non-Toxic Cryopreservation](https://x-therma.com/news/reducing-adverse-events-and-improving-outcomes-during-and-after-cell-and-gene-therapy-with-dmso-free-non-toxic-cryopreservation/): Cryopreservation for cell and gene therapies has long been a crucial consideration for drug developers and manufacturers. These modalities require... - [From Arctic Fish To New Cell Therapy Preservation Technologies](https://x-therma.com/news/from-arctic-fish-to-new-cell-therapy-preservation-technologies/): Cryopreservation should maintain the function and viability of organs and cell therapies, but the process is riddled with challenges. Can... - [Improving Health Equity Through Worldwide Organ Sharing](https://x-therma.com/news/improving-health-equity-through-worldwide-organ-sharing/): The organ transplantation field has experienced numerous barriers which have contributed to the creation of organ accessibility issues worldwide. To... - [Emerging Therapies Face Development Hurdles](https://x-therma.com/news/emerging-therapies-face-development-hurdles/): While traditional biologics continue to see strong market demand, the need for emerging therapies, such as regenerative medicines, has also... - [X-Therma Receives FDA Breakthrough Device Designation for XT-ViVo® Preservation Solution and TimeSeal® Organ Transport Device](https://x-therma.com/news/therma-receives-fda-breakthrough-device-designation-for-xt-vivo-preservation-solution-and-timeseal-organ-transport-device/): X-Therma Inc. , a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation – announced today that The... - [X-Therma Brings Biomimetics to Bioprocessing](https://x-therma.com/news/x-therma-brings-biomimetics-to-bioprocessing/): In the past two years, the cold chain turned into one of the most talked-about aspects of healthcare. Biotechnology company... - [Preserving Cell and Gene Therapies Without Using Toxins](https://x-therma.com/news/preserving-cell-and-gene-therapies-without-using-toxins/): Every day it seems you can find a headline somewhere describing the extraordinary progress scientists have made in developing cell... - [Article Discover Magazine: The People Making Organ Transplants More Efficient](https://x-therma.com/news/article-discover-magazine-the-people-making-organ-transplants-more-efficient/): Existing and emerging biotech advances are transforming the way we preserve and transport donated organs. While their methods may vary,... - [The Next Generation of Cryopreservation Technology](https://x-therma.com/news/the-next-generation-of-cryopreservation-technology/): Living cells, tissues, and organs are more critical to medicine than ever before, but current cryopreservation techniques are not enough... - [X-Therma Announces Oversubscribed Series A Financing](https://x-therma.com/news/x-therma-announces-oversubscribed-series-a-financing/): RICHMOND, Calif. — December 22, 2021 — 6:00 AM PT — X-Therma Inc. , a biotechnology company developing breakthrough technology... - [New Published Article in Bone Marrow Transplantation](https://x-therma.com/news/new-published-article-in-bone-marrow-transplantation/): What a great way to wrap up our collaborative work with Vitalant Research Institute, Marcus Muench, Philip Norris in Bone... - [Join for the excitement of pushing boundaries in organ preservation!](https://x-therma.com/news/join-for-the-excitement-of-pushing-boundaries-in-organ-preservation/): “Is it possible to achieve successful VCA transplantation after 72hrs ischemia at sub-zero temperature? ” @X-Therma is pleased to get... - [X-Therma welcomes Jim Greenwood to its Advisory Board.](https://x-therma.com/news/jim-greenwood-and-robin-farmanfarmaian-join-x-therma-advisory-board/): Chairman, BVGH Board of Directors; President & CEO, Biotechnology Innovation Organization (2005 – 2020) Jim is the outgoing President &... - [We are honored to be featured in the May Issue of AIChE!](https://x-therma.com/news/we-are-honored-to-be-featured-in-the-may-issue-of-aiche/): We are honored to be featured in the May Issue of AIChE – American Institute of Chemical Engineers. Special thank... - [X-Therma is Awarded for NSF Grants Continuously!](https://x-therma.com/news/x-therma-is-awarded-for-nsf-grant-continuously/): X-Therma was supported early on by the National Science Foundation (NSF) to develop ice-interactive biomimetic nanomaterial to advance biopreservation for... - [Organ Missing in Transit Shall be Preventable](https://x-therma.com/news/organ-missing-in-transit-shall-be-preventable/): Sad but true. It’s astonishing to see the number of lives impacted. “In a nation where nearly 113,000 people are... - [X-Therma is one of the winners of the Nanoart Image Contest](https://x-therma.com/news/x-therma-is-one-of-the-winners-of-the-2019-nanoart-image-contest/): X-Therma competed at the Molecular Foundry’s NanoArt Image Contest. The contest is held annually, to celebrate the National Nano Day.... - [X-Therma Selected as Buzz of Bio Winner](https://x-therma.com/news/x-therma-selected-as-buzz-of-bio-winner/): X-Therma has been selected as a Buzz of Bio winner in the category Diagnostics and Beyond! Thanks to everyone who... - [X-Therma was awarded the global health prize from bayer](https://x-therma.com/news/x-therma-was-awarded-the-global-health-prize-from-bayer/): “Throughout the year, Hello Tomorrow partners with top universities, research labs, accelerators and incubators around the globe to find entrepreneurs... - [First Place in SVIEF-STAR Final, Silicon Valley](https://x-therma.com/news/first-place-in-svief-star-final-silicon-valley/): X-Therma Inc. received 1st place in the fierce top 15 competition to win the 2018 annual SVIEF Star Award. - [Second Place of MTEC Final, QingDao](https://x-therma.com/news/second-place-of-mtec-final-qingdao/): X-Therma Inc. received 2nd place for the 2018 International Marine Innovation and Entrepreneurship Competition in Qingdao, China for XT-ViVo, the... - [The Big Chill-A UB alumna’s startup aims to revolutionize organ transplants through cryopreservation](https://x-therma.com/news/the-big-chill-a-ub-alumnas-startup-aims-to-revolutionize-organ-transplants-through-cryopreservation/) - [Confidence with XT-ViVo](https://x-therma.com/news/confidence-xt-vivotm/): X-Therma CEO Dr. Xiaoxi Wei welcomed her first baby into the world and is proud he became the first donor... - [X-Therma is selected by the California Institute of Regenerative Medicine (CIRM) for highly competitive funding](https://x-therma.com/news/x-therma-selected-california-institute-regenerative-medicine-cirm-highly-competitive-funding/): X-Therma is selected by the California Institute of Regenerative Medicine (CIRM) for highly competitive funding to fuel X-Therma’s development to... - [X-Therma is competitively selected for a third US Department of the Army SBIR Phase II SBIR contract](https://x-therma.com/news/x-therma-competitively-selected-third-us-department-army-sbir-phase-ii-sbir-contract/): X-Therma is competitively selected for a third US Department of the Army SBIR Phase II SBIR contract. X-Therma’s CryomatrixTM is... - [X-Therma CEO Dr. Xiaoxi Wei’s career development story is featured in Chemical &Engineering News](https://x-therma.com/news/x-therma-ceo-dr-xiaoxi-weis-career-development-story-featured-chemical-engineering-news/): X-Therma CEO Dr. Xiaoxi Wei’s career development story is featured in Chemical &Engineering News (C&EN, Volume 95 Issue 23 |... - [X-Therma is competitively selected for a second US Department of Defense Phase II SBIR contract](https://x-therma.com/news/x-therma-competitively-selected-second-us-department-defense-phase-ii-sbir-contract/): X-Therma is competitively selected for a second US Department of Defense Phase II SBIR contract. This contract funds genitourinary organ... - [X-Therma is featured in “Wirtschaftswoche” – Top weekly magazine in German Economy](https://x-therma.com/news/x-therma-featured-wirtschaftswoche-top-weekly-magazine-german-economy/): X-Therma is featured in “Wirtschaftswoche“ – top weekly magazine in German Economy. —59 Valley Talk: Investoren begeistern sich für Transplantationstechnik,... - [Talk of the Future at Two b_AHEAD THINK!TANK Fifteenth Annual Future Congress in Germany](https://x-therma.com/news/future-talk-2b-ahead-congress-germany/): Future talk at 2b AHEAD Congress 2016 in Germany – Our CEO Xiaoxi Wei shared our future vision on saving... - [X-Therma is competitively selected by for a US Department of Defense Phase II SBIR contract](https://x-therma.com/news/x-therma-is-competitively-selected-by-for-a-us-department-of-defense-phase-ii-sbir-contract/): X-Therma is competitively selected by for a US Department of Defense Phase II SBIR contract. Murine heart transplants will be... - [X-Therma Inc. won the Patrick Soon-Shiong Innovation Award hosted by the Los Angeles Business Journal](https://x-therma.com/news/x-therma-inc-won/): Congratulations to X-Therma Inc. for the Patrick Soon-Shiong Innovation Award 2015 hosted by the Los Angeles Business Journal! - [X-Therma at the Atomic precision for medical application workshop hosted by Foresight institute](https://x-therma.com/news/x-therma-atomic-precision-medical-application-workshop-hosted-foresight-institute/): Fun debut at the Atomic precision for medical application workshop hosted by Foresight institute. - [X-Therma is granted by U.S. Department of Defense for Phase I research](https://x-therma.com/news/x-therma-granted-u-s-department-defense-phase-research/): X-Therma is granted by U. S. Department of Defense for Phase I research on developing breakthrough cryoprotective agents (CPAs) for... --- ## White Papers --- ## Jobs --- # # Detailed Content ## Pages > Contact X-Therma – we'd love to hear from you! Fill out the contact form and we will reach out to you as soon as possible. - Published: 2025-09-25 - Modified: 2025-09-25 - URL: https://x-therma.com/products/xt-thrive/xt-thrive-thank-you/ Contact Us AddressNorth America625 Alfred Nobel DriveSuite BHercules, CA 94547USAEUROPEKaiserjägerstraße 306020 InnsbruckAustria Linkedin Facebook Thank you! Thank You for Getting in Touch! An X-Therma team member will be in contact with you shortly. --- > Contact X-Therma – we'd love to hear from you! Fill out the contact form and we will reach out to you as soon as possible. - Published: 2025-09-25 - Modified: 2025-09-25 - URL: https://x-therma.com/contact-thank-you/ Contact Us AddressNorth America625 Alfred Nobel DriveSuite BHercules, CA 94547USAEUROPEKaiserjägerstraße 306020 InnsbruckAustria Linkedin Facebook Thank you! Thank You for Getting in Touch! An X-Therma team member will be in contact with you shortly. --- > We're combating organ shortage with a breakthrough organ preservation solution that prevents ice from forming on organs, cells, and tissues. - Published: 2025-09-11 - Modified: 2025-11-05 - URL: https://x-therma.com/products/xt-vivo-timeseal/ XT-Vivo® & TimeSeal® Multi-Day Preservation of Organs, Tissues and Cells The global shortage of transplantable organs is considered one of the greatest modern medical crises. Only 10% of the worldwide transplantation needs are being met. Every hour in the US, at least one patient dies while waiting for a life-saving organ. Donor availability is one part of the equation... the other is time. XT-ViVo® & TimeSeal® will enable multi-day preservation and remove time from the equation. Check out our white paper on organ ischemia to learn more! Organ Transplant Not Enough Time Do you know 80% of transplantable organs end up NOT being transplanted today, especially for hearts and lungs? 90% UNMET NEED 1/hour Die on waitlist 80% transplantable organs left unused Just hours to keep organs alive In organ transplantation, we are racing against TIME on Ice every day, battling an extremely slim window where every minute matters. We currently perfuse and store an organ in preservation solution that is kept between 2-8°C in an igloo cooler on wet-ice. This only allows organ survival for less than a day. For the heart, that is an ephemeral 4 hrs. This extremely tight race severely hinders organ accessibility, breeds extreme risk, creates a logistics nightmare for the transplant team and significantly impacts patient survival. To win such a race, we MUST remove TIME from the equation. In Vitro Fertilization Can we say “No” to toxins for healthy babies? DMSO Adverse Toxicity & Genotoxicity Poor Functional Recovery --- > Contact X-Therma – we'd love to hear from you! Fill out the contact form and we will reach out to you as soon as possible. - Published: 2025-08-28 - Modified: 2025-11-05 - URL: https://x-therma.com/products/xt-thrive/xt-thrive-contact/ Request Quote CONTACTinfo@x-therma. comAddressNorth America625 Alfred Nobel DriveSuite BHercules, CA 94547USAEUROPEKaiserjägerstraße 306020 InnsbruckAustria Linkedin Facebook --- > Our platform enables safe and effective cryopreservation for all regenerative medicines without DMSO, serum or other unknown components. - Published: 2024-10-03 - Modified: 2025-11-05 - URL: https://x-therma.com/products/xt-thrive/ XT-Thrive® DMSO-free, Chemically-Defined, Safe & Effective Cryopreservation Solution XT-Thrive® is a DMSO-free and non-toxic cryopreservation solution. It is chemically defined and absent of any serum or recombinant proteins. It was designed for the preservation of primary stem cells and tissues at ultra-low temperatures (-70°C to -196°C). XT-Thrive® is tailored to provide increased recovery and functionality of cryopreserved biospecimens over conventional cryopreservation media. XT-Thrive® is cGMP grade and plug and play for cell and tissue manufacturing processes. Request Quote The Problem For Cell Manufacturing, DMSO and Serum No Longer Meet Integrated Demands Poor Performance • Poor post-thaw cell survival as low as 15-20% • Cell functionality impaired Toxic* • Profound in vivo toxicity • Severe injection site pain/neurotoxicity • Adverse Genotoxicity Hindered Scalability • Processing nightmare • Limited scale-up production • Batch variation Biopreservation is the key for commercial cell manufacturing & processing, which happens 3-5 times throughout the process. However, preservation has seen little improvement. Existing standards use 5-10% dimethyl sulfoxide (DMSO) with serum. A new solution is needed to enable “off-the-shelf” living medicines. *Nature, Scientific Reports volume 9, Article number: 4641 (2019) Benefits of XT-Thrive® XT-Thrive® enables non-toxic cryopreservation for life-saving regenerative medicines such as vaccines, cell & gene therapies, and engineered tissues. DMSO-FREE AND NON-TOXIC XT-Thrive® is a non-toxic and non-genotoxic cryopreservation solution that reduces the risks of adverse alterations in cellular phenotype during preservation and clinical side effects during and after cell therapy. Chemically Defined XT-Thrive® is a fully chemically defined formulation and contains no serum or... --- > At X-Therma, we're advancing regenerative medicine and organ transplantation with a novel biopreservation solution. - Published: 2024-10-02 - Modified: 2025-10-30 - URL: https://x-therma.com/ Preserving Life by Emulating Nature X-Therma pioneers a breakthrough biopreservation platform, transforming “living” medicines into on demand treatments. We empower patients with access to safe, reliable organs, engineered tissues, and advanced cell & gene therapies, dismantling the obstacles of time and distance. See Products > Products For Cell and Tissue Cryopreservation XT-Thrive® cGMP grade, DMSO-free and non-toxic cryopreservation media perfected for clinical & commercial translation at ultra-low temperatures (-70°C to -196°C). Discover more For Kidney Preservation XT-ViVo® and TimeSeal® XT-ViVo® and TimeSeal® received FDA Breakthrough Device Designation in 2022. This turnkey solution stores kidneys for up to 5 days at high subzero temperatures for transplantation. Discover more X-Therma’s biopreservation breakthroughs are solving these problems. Organ Transplant Cell Manufacturing In Vitro Fertilization Organ Transplant The Problem Not Enough Time 90% Unmet Needs 80% Transplantable Organs Left Unused Just Hours to Keep Organs Alive 1 Per Hour Die on Waitlist Did you know that 80% of transplantable organs are NOT being transplanted, especially hearts and lungs? In organ transplantation, we are racing against TIME on Ice every day, battling an extremely slim window where every minute matters. We currently perfuse and store an organ in preservation solution that is kept between 2-8°C in an igloo cooler on wet-ice. This only allows organ survival for less than a day. For the heart, that is an ephemeral 4 hrs. This extremely tight race severely hinders organ accessibility, breeds extreme risk, creates a logistics nightmare for the transplant team and significantly impacts patient survival. To... --- - Published: 2022-12-14 - Modified: 2024-08-14 - URL: https://x-therma.com/career/jobs/ We believe in investing in people and building meaningful relationships People are the heart and soul of X-Therma. Without our team we would not be able to make strides towards accomplishing our goals. This is why we invest in people and equip them with the tools and skills they need to grow and take on bigger challenges. Apply Now! We're excited that you're applying to X-Therma, and we can't wait to learn more about you. View Our Current Openings --- - Published: 2022-12-14 - Modified: 2023-07-27 - URL: https://x-therma.com/company/about/ Removing Time from the Equation X-Therma enables the robust preservation of cells, tissues, organs, and other biologics by leveraging our proprietary peptoid. The peptoid inhibits lethal ice crystals, allowing long-term sub-zero storage of biological materials while maintaining unparalleled functionality and viability. Our Values How it Began When she was 8 years old, Xiaoxi's beloved grandfather passed away. If he had received a donor liver, he would have had more time to spend with loved ones. Xiaoxi has since dedicated her life to finding a solution that increases organ availability. In 2014 she obtained her doctorate in medicinal chemistry from SUNY-Buffalo. Soon after, she established X-Therma to bring her vision of eradicating organ waitlists to life. X-Therma History 2015Xiaoxi Wei, CEO began her research work for X-Therma at Lawrence Berkeley National Laboratory. She received her first grant awarded to X-Therma. Provisional patent filed. 2016Only one year later X-Therma had two additional grants in implementation and a team of four. First successful proof of concept for novel preservation of cell lines. 2017X-Therma now has five grants running simultaneously and filed additional provisional patents. 2018X-Therma partnered with Johns Hopkins University and Dr. Gerald Brandacher on several grants. X-Therma awarded first patent claim set! 2019Successful in vivo mouse heart transplant with Johns Hopkins University. 2020X-Therma survived the Covid-19 pandemic and was able to continue with successful ex vivo organ transplantations. 2021X-Therma closed an oversubscribed $13M Series A financing led by LOREA AG. The European office was opened. 2022The FDA designated X-Therma's proprietary organ preservation... --- - Published: 2022-12-14 - Modified: 2022-12-19 - URL: https://x-therma.com/imprint/ Imprint X-Therma Inc. 2600 Hilltop DriveSuite B220Richmond, CA 94806X-Therma GmbHKaiserjägerstraße 30A-6020 InnsbruckFN 564408 mATU77414308Email: info@x-therma. comManagement:Mark Kline, Ph. D. Xiaoxi Wei, Ph. D. --- - Published: 2022-12-14 - Modified: 2022-12-19 - URL: https://x-therma.com/data-policy/ Privacy Policy 1. An overview of data protectionGeneral informationThe following information will provide you with an easy to navigate overview of what will happen with your personal data when you visit this website. The term “personal data” comprises all data that can be used to personally identify you. For detailed information about the subject matter of data protection, please consult our Data Protection Declaration, which we have included beneath this copy. Data recording on this websiteWho is the responsible party for the recording of data on this website (i. e. , the “controller”)? The data on this website is processed by the operator of the website, whose contact information is available under section “Information about the responsible party (referred to as the “controller” in the GDPR)” in this Privacy Policy. How do we record your data? We collect your data as a result of your sharing of your data with us. This may, for instance be information you enter into our contact form. Other data shall be recorded by our IT systems automatically or after you consent to its recording during your website visit. This data comprises primarily technical information (e. g. , web browser, operating system, or time the site was accessed). This information is recorded automatically when you access this website. What are the purposes we use your data for? A portion of the information is generated to guarantee the error free provision of the website. Other data may be used to analyze your user patterns. What rights... --- - Published: 2022-12-13 - Modified: 2022-12-21 - URL: https://x-therma.com/references/ References Home Verheijen, M. et al. (2019) “DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro,” Scientific Reports 9, 4641(2019). XT-Thrive® Verheijen, M. et al. (2019) “DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro,” Scientific Reports 9, 4641(2019). --- > X-Therma Team Excellence is spread out across the U.S. and Europe, hired for the expertise and attributes that they bring to the table. - Published: 2022-12-09 - Modified: 2026-02-05 - URL: https://x-therma.com/company/team/ Meet the Team Xiaoxi (Sofie) Wei, Ph. D CEO & Co-founderLinkedInis an award-winning American entrepreneur and inventor in the area of biomimetic nanoscience and biopreservation in Regenerative Medicine. Being persistent in her life vision to enable “on-demand organs” from a very young age, she pursued her scientific endeavor in biomimetic Chemistry at SUNY Buffalo, earning her doctorate. Inheriting the entrepreneurial spirit from her family, she successfully managed $8M in engineering projects while completing her Ph. D. Then she founded X-Therma in the San Francisco Bay Area in Oct 2014 to bring lab innovation to patients. Dr. Wei is the inventor of X-Therma’s core technologies based on biomimetic hyper-effective ice prevention materials and devices, resulting in 17 issued global patents. She has served as principal investigator or co-PI of 12 national and international innovation research grants with accumulated value exceeding $14M USD from DoD, NSF, NIH, CIRM, EU etc. She has led the X-Therma research endeavors at The Molecular Foundry, Lawrence Berkeley National Laboratory 2015-2024. She serves as a healthcare advisor for the UC Regents working group on innovation transfer and entrepreneurship, is a scientific advisor for Life Extension Foundation, and was the Vice Chair of the Younger Chemists Committee of the American Chemical Society (ACS), and Cal ACS Executive Committee Member. She is currently a distinguished member of the RULEBREAKER Society, in Germany. Mark Kline, Ph. D. COO & Co-founder LinkedInMark Kline has been continuously involved in research at the interplay of chemistry and biology and is an expert in... --- > Win the race against time with us using cell and organ cryopreservation solutions that are changing regenerative medicine. - Published: 2022-12-09 - Modified: 2023-07-27 - URL: https://x-therma.com/career/why-x-therma/ Join the Race Against Time At X-Therma you will have an opportunity to collaborate with some incredible people. We are all united by a shared passion for using our unique superpowers to help improve patient outcomes. The advances we are making in biopreservation can have a tremendous effect on people's lives — and that keeps us going. We believe great people make a great company! We come from a diverse range of backgrounds which leads to a collaborative, yet fast-paced, environment that inspires us to create, learn, think, and challenge each other every day. Diversity is in Our DNA At X-Therma we dream big, and our goal is to impact biopreservation on a global scale. One thing is clear, a global problem requires a global team. Our team comes from 5 continents and more than 20 countries around the world. We enjoy learning about each other's food, culture, and unique perspectives. Where does your heart call home? Our Values They guide us day-to-day and are at the heart of every decision we make. DreamGo big or go home. We never say never. ExcellenceWe take on touch challenges and put our best foot forward. (Yes, even those of us with two left feet. ) PerseveranceJust keep swimming. IntegrityWe do the right thing, especially when no one is watching. RespectTreat others the way they want to be treated. SupportTeamwork makes the dream work. We’re there for each other. Join our Team If X-Therma sounds like the place for you, what are you... --- > Join X-Therma for a cutting-edge position in biotechnology as we unlock a way to eliminate organ transplant waiting lists worldwide. - Published: 2022-12-08 - Modified: 2023-07-27 - URL: https://x-therma.com/career/ Careers X-Therma is on a mission to improve patient outcomes by providing preservation without compromise. Together we can ensure a world where we have Time. Our work is truly cross disciplinary, bringing together a multitude of disciplines including biology, chemistry, and engineering. We 🫀 X-Therma There's a million and one reasons we enjoy working at X-Therma.  Here's a few... See Why Join our Team We're racing against time. Are you up for the challenge? Find your perfect Role --- > X-Therma is helping reimagine biotime using ground-breaking cold chain technology to advance Regenerative Medicine. - Published: 2022-12-08 - Modified: 2023-08-10 - URL: https://x-therma.com/company/ Removing Time from the Equation X-Therma enables the robust preservation of cells, tissues, organs, and other biologics by leveraging our proprietary peptoid. The peptoid inhibits lethal ice crystals, allowing long-term sub-zero storage of biological materials while maintaining unparalleled functionality and viability. X-Therma is headquartered in Richmond, San Francisco Bay Area, and has expanded to Austria in Europe. Our Values About X-Therma A tragic loss during Xiaoxi’s childhood due to a lack of organs set her on a course to find answers. Nearly two decades later she founded X-Therma and the dream for readily available organs is about to turn into reality. Read more The Team It takes great people to build a great company, and we think ours are some of the best. Get to Know Them --- > Inspired by the behaviors of arctic fish, X-Therma has applied nanoscience to create advanced antifreeze proteins that prevent ice formation. - Published: 2022-12-08 - Modified: 2025-09-25 - URL: https://x-therma.com/science/ Science We Need Better Cryoprotectants Lowering temperature is one of the most effective ways to slow cellular metabolism and extend storage times for biological materials. Storage at temperatures below 0°C is limited by the formation of ice crystals. Traditional cryoprotectants used to overcome this hurdle, such as dimethyl sulfoxide (DMSO), are limited in effectiveness and toxic to the very materials they are supposed to protect. Inspired by Nature Arctic fish can survive in the most frigid subzero environments due to their ability to produce antifreeze proteins (AFPs). These proteins limit cellular damage by preventing the aberrant formation and growth of ice. We have pioneered a new class of cryoprotectants, inspired by natural antifreeze proteins, to effectively preserve life at subzero temperatures. Can Ice Play Nice? Polarized light reveals the life-saving secrets of antifreeze molecules. Water Water naturally freezes into large hexagonal ice crystals. X-Therma Antifreeze peptoid results in smaller, rounder, safer ice and even maintains crystal size during temperature excursions. Arctic Fish Antifreeze proteins from arctic fish alter the ice crystals into a dual pyramid shape. The Power of Peptoids Taking inspiration from naturally occurring anti-freeze proteins, X-Therma has developed novel biomimetic molecules called peptoids to act as highly-effective cryoprotectants. These peptoids allow for controlled ice formation and deterred recrystallization with an unprecedented freezing point depression at temperatures down to -196°C. Adding to their versatility, they can be utilized for the stable ice-free storage of cells, tissues, and whole organs at sub-zero ( --- > We're combating organ shortage with a breakthrough organ preservation solution that prevents ice from forming on organs, cells, and tissues. - Published: 2022-12-07 - Modified: 2025-09-11 - URL: https://x-therma.com/products/xt-vivo-timeseal-old/ XT-VIVO® & TIMESEAL® Multi-Day Preservation of Organs, Tissues and Cells The global shortage of transplantable organs is considered one of the greatest modern medical crises. Only 10% of the worldwide transplantation needs are being met. Every hour in the US, at least one patient dies while waiting for a life-saving organ. Donor availability is one part of the equation... the other is time. XT-ViVo® & TimeSeal® will enable multi-day preservation and remove time from the equation. Check out our white paper on organ ischemia to learn more! Organ Transplant Not Enough Time Do you know 80% of transplantable organs end up NOT being transplanted today, especially for hearts and lungs? 1/hour Die on waitlist 80% transplantable organs left unused Just hours to keep organs alive In organ transplantation, we are racing against TIME on Ice every day, battling an extremely slim window where every minute matters. We currently perfuse and store an organ in preservation solution that is kept between 2-8°C in an igloo cooler on wet-ice. This only allows organ survival for less than a day. For the heart, that is an ephemeral 4 hrs. This extremely tight race severely hinders organ accessibility, breeds extreme risk, creates a logistics nightmare for the transplant team and significantly impacts patient survival. To win such a race, we MUST remove TIME from the equation. With X-Therma's biopreservation breakthroughs, we make a difference. In Vitro Fertilization Can we say “No” to toxins for healthy babies? DMSO Adverse Toxicity & Genotoxicity Poor Functional Recovery --- > Our platform enables safe and effective cryopreservation for all regenerative medicines without DMSO, serum or other unknown components. - Published: 2022-12-06 - Modified: 2024-10-04 - URL: https://x-therma.com/products/xt-thrive-old/ XT-THRIVE® DMSO-free, Chemically Defined, Safe & Effective Cryopreservation Solution XT-Thrive® is a DMSO-free, serum-free, protein-free, and chemically defined cryopreservation media for the preservation of mammalian cells at ultra-low temperatures (-70° C to -196° C). Designed and manufactured with the utmost quality in mind, XT-Thrive® is tailored to provide high cell recovery and functionality. It is a non-toxic & hyper-effective alternative to traditional cryopreservatives and is plug and play for cell & tissue manufacturing processes. Request a Quote Organ Transplant Not Enough Time Do you know 80% of transplantable organs end up NOT being transplanted today, especially for hearts and lungs? 90% UNMET NEED 1/hour Die on waitlist 80% transplantable organs left unused Just hours to keep organs alive In organ transplantation, we are racing against TIME on Ice every day, battling an extremely slim window where every minute matters. We currently perfuse and store an organ in preservation solution that is kept between 2-8°C in an igloo cooler on wet-ice. This only allows organ survival for less than a day. For the heart, that is an ephemeral 4 hrs. This extremely tight race severely hinders organ accessibility, breeds extreme risk, creates a logistics nightmare for the transplant team and significantly impacts patient survival. To win such a race, we MUST remove TIME from the equation. With X-Therma's biopreservation breakthroughs, we make a difference. cGMP CELL & GENE THERAPY DMSO and Serum No Longer Meet Integrated Demands Poor Performance Poor post-thaw cell survival as low as 15-20% Cell functionality impaired Toxic... --- > X-Therma's biopreservation platform enables long-term storage to win the race again time for transplants, and cell & gene therapy. - Published: 2022-12-05 - Modified: 2025-03-13 - URL: https://x-therma.com/products/ A Biopreservation Platform Without Compromise X-Therma enables the robust preservation of cells, tissues, organs, and other biologics by leveraging our proprietary peptoid. The peptoid inhibits lethal ice crystals, allowing long-term sub-zero storage of biological materials while maintaining unparalleled functionality and viability. Out products are chemically defined, as well as DMSO-free, serum-free, and protein-free. --- > Get the latest X-Therma Inc. news about cryopreservation and biopreservation and the important work we're doing to eliminate organ storages. - Published: 2022-12-01 - Modified: 2025-08-26 - URL: https://x-therma.com/newsroom/ X-Therma's Latest News Read the latest news about X-Therma, Cryopreservation and Biopreservation. Filter By Category: XT-ThriveXT-ViVo & TimeSeal Filter By Topic: CryopreservationOrgan Preservation --- - Published: 2022-12-01 - Modified: 2024-07-26 - URL: https://x-therma.com/contact/thank-you/ Thank You Your time is valuable. A member of our team will be in touch within 24 hours to discuss your service request. Thank you. Explore Products --- - Published: 2022-10-18 - Modified: 2022-11-03 - URL: https://x-therma.com/resources/ Resources Looking for data, research backed studies, and helpful tips and recommendations from industry experts? You came to the right page. Articles See more articles Downloads See more Videos See more videos Resource Type See more Subscribe to our newsletter Subscribe to our newsletter --- - Published: 2022-07-06 - Modified: 2022-12-14 - URL: https://x-therma.com/consent/ Consent Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Sed pulvinar proin gravida hendrerit. In nulla posuere sollicitudin aliquam. Viverra accumsan in nisl nisi. Venenatis a condimentum vitae sapien pellentesque habitant morbi tristique. Nisi lacus sed viverra tellus in hac habitasse. Dolor sed viverra ipsum nunc. Aliquam malesuada bibendum arcu vitae elementum curabitur vitae nunc. Dictum at tempor commodo ullamcorper a lacus vestibulum sed arcu. Aliquam sem fringilla ut morbi tincidunt augue interdum velit euismod. Duis at tellus at urna condimentum mattis pellentesque id nibh. Molestie at elementum eu facilisis. Sit amet purus gravida quis blandit turpis cursus in hac. In nisl nisi scelerisque eu ultrices. Eros in cursus turpis massa tincidunt dui ut ornare. Scelerisque viverra mauris in aliquam sem fringilla ut morbi tincidunt. Neque vitae tempus quam pellentesque nec nam. In ante metus dictum at. Velit sed ullamcorper morbi tincidunt ornare massa eget egestas purus. Viverra nam libero justo laoreet sit amet cursus sit. Dictumst quisque sagittis purus sit amet. Egestas purus viverra accumsan in nisl nisi scelerisque eu ultrices. Et netus et malesuada fames. Praesent tristique magna sit amet. Neque viverra justo nec ultrices dui sapien. Blandit turpis cursus in hac habitasse platea dictumst. Sed elementum tempus egestas sed sed risus pretium. Urna id volutpat lacus laoreet non curabitur gravida arcu ac. Diam quam nulla porttitor massa id neque aliquam vestibulum morbi. Sollicitudin aliquam ultrices sagittis orci a scelerisque purus semper eget. Praesent elementum facilisis leo... --- > Contact X-Therma – we'd love to hear from you! Fill out the contact form and we will reach out to you as soon as possible. - Published: 2022-05-26 - Modified: 2025-08-28 - URL: https://x-therma.com/contact/ Contact Us CONTACTinfo@x-therma. comAddressNorth America625 Alfred Nobel DriveSuite BHercules, CA 94547USAEUROPEKaiserjägerstraße 306020 InnsbruckAustria Linkedin Facebook --- > At X-Therma, we're advancing regenerative medicine and organ transplantation with a novel biopreservation solution. - Published: 2022-05-03 - Modified: 2024-10-04 - URL: https://x-therma.com/home-old/ Preserving Life by Emulating Nature A robust preservation platform for cells, tissues, organs, and regenerative medicines. See Products > We advance regenerative medicine and organ transplantation with a ground-breaking biopreservation platform. We enable patient access to safe and reliable organs, engineered tissues, and cell therapies, breaking down the barriers of time and distance. You have Time. Organ Transplant Not Enough Time Do you know 80% of transplantable organs end up NOT being transplanted today, especially for hearts and lungs? 90% UNMET NEED 1/hour Die on waitlist 80% transplantable organs left unused Just hours to keep organs alive In organ transplantation, we are racing against TIME on Ice every day, battling an extremely slim window where every minute matters. We currently perfuse and store an organ in preservation solution that is kept between 2-8°C in an igloo cooler on wet-ice. This only allows organ survival for less than a day. For the heart, that is an ephemeral 4 hrs. This extremely tight race severely hinders organ accessibility, breeds extreme risk, creates a logistics nightmare for the transplant team and significantly impacts patient survival. To win such a race, we MUST remove TIME from the equation. With X-Therma's biopreservation breakthroughs, we make a difference. cGMP CELL & GENE THERAPY DMSO and Serum No Longer Meet Integrated Demands Poor Performance Poor post-thaw cell survival as low as 15-20% Cell functionality impaired Toxic Profound in vivo toxicitySevere injection site pain/neurotoxicityAdverse GenotoxicityNature, Scientific Reports volume 9, Article number: 4641 (2019) Hindered Scalability Processing nightmareLimited scale-up... --- --- ## Posts --- ## News - Published: 2025-07-02 - Modified: 2025-08-26 - URL: https://x-therma.com/news/x-therma-showcases-groundbreaking-organ-preservation-technology-at-johns-hopkins-hopkins-on-the-hill-event/ X-Therma proudly announces its participation in the prestigious Hopkins on the Hill event, held on June 11, 2025, in Washington, D.C. The biennial event showcased the most impactful federally funded research and innovations across various fields. Source: PR Newswire HERCULES, Calif. , July 2, 2025 /PRNewswire/ -- X-Therma Inc. , a pioneering biotechnology company revolutionizing organ preservation and regenerative medicine, proudly announces its participation in the prestigious Hopkins on the Hill event, held on June 11, 2025, in Washington, D. C. Hosted by Johns Hopkins University, the biennial event showcased the most impactful federally funded research and innovations across various fields, including artificial intelligence, healthcare technology, and organ transplantation. X-Therma's XT-ViVo® & TimeSeal® a next-generation organ preservation system, was featured as one of the 20 groundbreaking technologies presented at the event. The system, which enables ice-free organ preservation at subzero temperatures, was highlighted as a transformative solution that could significantly increase the availability of viable organs for transplantation, reduce the risk of organ rejection, and facilitate transplant donation and surgery operations. The technology was presented by Dr. Gerald Brandacher, Dr. Byoung Chol Oh, and Amanda Loftin, PhD, DVM from Johns Hopkins University, with attendees including members of the U. S. Senate. XT-ViVo® and TimeSeal® was recognized as one of the 16 new discoveries that have the potential to save lives, further cementing X-Therma's position as a leader in the field of sub-zero ice-free organ preservation. A Leap Forward in Organ Transplantation XT-ViVo® leverages X-Therma's proprietary antifreeze peptoids, inspired by Arctic species, to prevent ice crystal formation during preservation. Combined with the smart transporter TimeSeal®, this innovative platform extends the viable preservation time of organs from hours to multiple days by enabling ice-free storage at sub-zero temperature,... --- > X-Therma Inc., a pioneering biotechnology company focused on revolutionizing regenerative medicine through its innovative biopreservation platform, today announced the appointment of Neil Warma, a seasoned healthcare entrepreneur with over 25 years of experience in managing and advising numerous biotechnology and pharmaceutical companies globally, to its Board of Directors. This strategic addition comes as X-Therma continues to advance its mission of transforming “living” medicines into on-demand treatments, addressing critical needs in organ transplantation and the rapidly evolving field of cell and gene therapies. - Published: 2025-06-10 - Modified: 2025-08-26 - URL: https://x-therma.com/news/x-therma-welcomes-biotech-veteran-neil-warma-to-its-board-of-directors/ X-Therma announced the appointment of Neil Warma, a seasoned healthcare entrepreneur with over 25 years of experience in managing and advising numerous biotechnology and pharmaceutical companies globally, to its Board of Directors. Source: PR Newswire HERCULES, CA- Date – X-Therma Inc. , a pioneering biotechnology company focused on revolutionizing regenerative medicine through its innovative biopreservation platform, today announced the appointment of Neil Warma, a seasoned healthcare entrepreneur with over 25 years of experience in managing and advising numerous biotechnology and pharmaceutical companies globally, to its Board of Directors. This strategic addition comes as X-Therma continues to advance its mission of transforming “living” medicines into on-demand treatments, addressing critical needs in organ transplantation and the rapidly evolving field of cell and gene therapies. X-Therma's groundbreaking technologies, including XT-Thrive®, a cGMP grade, DMSO-free cryopreservation media for cells and tissues, and XT-ViVo® & TimeSeal®, a solution for extending the preservation of organs like kidneys (which received FDA Breakthrough Device Designation), are poised to significantly impact patient outcomes by overcoming the limitations of time and distance in the delivery of life-saving therapies. The wealth of experience Neil Warma brings to the board is expected to be instrumental in guiding X-Therma through its next phase of growth and development, further solidifying its position as a leader in biopreservation innovation. “Recognizing X-Therma’s groundbreaking technology and its vast potential, I am pleased to join the Board,” said Neil Warma. “My passion lies in advancing breakthrough innovations that enhance our healthcare system and drive meaningful improvements in patient outcomes. X-Therma’s mission to revolutionize transplant medicine aligns perfectly with this vision. Beyond transplantation, its pioneering work in biopreservation is set to play a vital role in scaling up and scaling out... --- - Published: 2024-10-23 - Modified: 2025-08-26 - URL: https://x-therma.com/news/x-therma-achieves-worlds-first-subzero-organ-transports-multiple-48-hour-transatlantic-journeys-support-first-steps-toward-tackling-organ-waitlist/ Surgeons successfully transported pig kidneys between Baltimore and Innsbruck five times using X-Therma's FDA Breakthrough-designated subzero preservation technology Image: Dr. Gerald Brandacher and team of surgical staff from Johns Hopkins University School of Medicine and Medical University of Innsbruck, Xiaoxi Wei, Ph. D. , Co-Founder and CEO of X-Therma, Mark Kline, Ph. D. , Co-founder and CTO of X-Therma with the TimeSeal® Source: PR Newswire San Francisco, CA, October 23, 2024 - In a world first, a pig kidney preserved at subzero temperatures was successfully transported across the Atlantic Ocean multiple times, demonstrating the potential for a novel technology to greatly extend organ storage and preservation, and make long-distance organ transportation a clinical reality. Extending organ preservation time could bridge the organ supply-and-demand gap, avoid high-risk, time-critical emergency surgeries, and potentially achieve advanced genetic matching, ultimately leading to more transplants and saving more lives. Dr. Gerald Brandacher led a surgical and research team that removed a kidney from a pig at the Johns Hopkins University School of Medicine in Baltimore, Maryland, and transported the kidney on a commercial aircraft to the Medical University of Innsbruck in Austria. Preserved for roughly 48 hours at subzero temperatures, the kidney was assessed in Innsbruck on a clinical-grade machine perfusion device and demonstrated viability and functionality. The team repeated the process five times in the past 12 months with preservation times ranging from 48-72 hours. As proof of concept of the technology, the team performed a life-supporting transplant in a pig, with the kidney maintaining normal renal function during the entire observation period for 200 days post-transplant after 72 hours ice-free subzero... --- - Published: 2024-05-29 - Modified: 2024-10-04 - URL: https://x-therma.com/news/x-therma-achieves-gmp-commercial-readiness-with-xt-thrive/ X-Therma Inc., a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, has achieved GMP (Good Manufacturing Practice) commercial readiness with its flagship product, XT-Thrive®. X-Therma Inc. , a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, has achieved GMP (Good Manufacturing Practice) commercial readiness with its flagship product, XT-Thrive®. XT-Thrive® enables non-toxic cryopreservation for life-saving regenerative medicines such as vaccines, cell lines for production, cell and gene therapies, and engineered tissues. The DMSO-free, serum-free, protein-free, and chemically defined cryopreservation media is designed to significantly enhance the preservation of biological materials, offering unprecedented efficiency and reliability. "This announcement marks a critical step forward in ensuring the highest quality and scalability of XT-Thrive® for widespread clinical and commercial applications," said Mark Kline, co-founder and Chief Technology Officer at X-Therma. "This milestone not only opens new opportunities for advancing cryopreservation solutions that can save countless lives, but also marks the first time peptoids, an emerging class of biomimetic molecules, have been utilized at a market-ready scale. " In March 2024, X-Therma completed an oversubscribed $22. 4 million Series B funding round. The investment enables X-Therma to scale global commercial operations and facilitates the company's progression into the clinical stage. "With GMP commercial readiness, XT-Thrive® will meet the stringent quality and regulatory standards required for clinical use, positioning X-Therma as a key player in the biopreservation market," said Mike Osborne, SVP of Commercial, Regenerative Medicine at X-Therma. "This demonstrates our progression towards being able to meet increasing market demands and support large-scale clinical applications. " X-Therma has established an independent quality organization and a robust Quality Management System (QMS) that meets U. S. regulatory... --- - Published: 2024-04-30 - Modified: 2024-10-04 - URL: https://x-therma.com/news/x-therma-announces-xt-thrive-drug-master-file-dmf-accepted-by-u-s-food-and-drug-administration-fda/ X-Therma Inc., a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, announces that the Food and Drug Administration (FDA) accepted a Drug Master File (DMF) covering its product, XT-Thrive®. X-Therma Inc. , a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, announces that the Food and Drug Administration (FDA) accepted a Drug Master File (DMF) covering its product, XT-Thrive®. This DMF covers the Chemistry, Manufacturing and Controls (CMC) for this key chemistry innovation, which enables non-toxic cryopreservation for life-saving regenerative medicines. "This submission was the culmination of several years of development activities and the establishment of a Good Manufacturing Practices (GMP) manufacturing facility in Hercules, California," says Xiaoxi Wei, Ph. D. , co-founder and Chief Executive Officer of X-Therma. "We are poised to provide worldwide supply of this next-generation product intended for use within the biologics, gene therapy, tissue engineering, and cell therapy sectors. " X-Therma submitted the DMF to the FDA in January 2024, and the FDA accepted it on January 31, 2024. X-Therma clients who use the product to preserve therapeutic cells will be able to reference the DMF in their Investigational New Drug (IND) and Biologics License Application (BLA) submissions to the FDA for products in the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). XT-Thrive® is a DMSO-free, serum-free, protein-free, and chemically defined cryopreservation media enabling the preservation of mammalian cells at ultra-low temperatures (-70° C to -196° C). It incorporates a fundamentally new class of cryoprotectant, named peptoids, fully synthetic defined molecules are inspired by natural antifreeze proteins (hyper-effective and non-toxic) to prevent aberrant ice formation and risk of shock-induced ice damage.... --- - Published: 2024-03-13 - Modified: 2025-08-26 - URL: https://x-therma.com/news/x-thermas-22-4m-series-b-sets-stage-to-transform-regenerative-medicine-and-organ-transplantation/ X-Therma Inc., a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, has completed an oversubscribed $22.4 million Series B funding round. Image: Xiaoxi Wei, Ph. D. , Co-founder and CEO of X-Therma, with the TimeSeal® Oversubscribed round propels company towards clinical trials and global market expansion, promising to extend organ preservation times and revolutionize healthcare. Source : PR Newswire SAN FRANCISCO, March 13, 2024 /PRNewswire/ -- X-Therma Inc. , a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, has completed an oversubscribed $22. 4 million Series B funding round. The investment enables X-Therma to scale global commercial operations and facilitates the company's progression into the clinical stage with Food and Drug Administration (FDA) Breakthrough Device status, aimed at significantly increasing organ availability for transplantation by overcoming time-sensitive limitations. The investment will advance multiple key products in X-Therma's development pipeline: XT-Thrive® and XT-NoVoTM for regenerative medicine and cell therapy and XT-ViVo® & TimeSeal® for organ preservation for transplantation. XT-ViVo® & TimeSeal® received FDA Breakthrough Device designation, which is given to products that have the potential to offer more effective diagnosis or treatment of life-threatening diseases with an unmet medical need. "This funding marks a pivotal moment as we prepare to launch our GMP-grade cryopreservation and cold-chain solutions into the commercial market, responding to growing demand in Cell and Gene Therapy and bioprocessing," says Dr. Xiaoxi Wei, Ph. D. , Co-founder and Chief Executive Officer of X-Therma. "It also propels us to the forefront of organ transplantation innovation, with our emerging products that could eliminate time as a critical constraint, with the potential to save millions of lives. "... --- - Published: 2023-12-14 - Modified: 2023-12-14 - URL: https://x-therma.com/news/preserve-mammalian-cells-at-ultra-low-temperatures-with-xt-thrive/ XT-Thrive® is a DMSO-free, serum-free, protein-free, and chemically defined cryopreservation media for the preservation of mammalian cells at ultra-low temperatures (-70° C to -196° C). Designed and manufactured with the utmost quality in mind, XT-Thrive® is tailored to provide high cell recovery and functionality. It is a non-toxic & hyper-effective alternative to traditional cryopreservatives and is plug and play for cell & tissue manufacturing processes. Read more --- - Published: 2023-12-14 - Modified: 2023-12-14 - URL: https://x-therma.com/news/xt-vivo-timeseal-multi-day-preservation-of-organs-tissues-and-cells/ Learn how XT-ViVo® & TimeSeal® will enable multi-day preservation and remove time from the equation. The global shortage of transplantable organs is considered one of the greatest modern medical crises. Only 10% of the worldwide transplantation needs arebeing met. Every hour in the US, at least one patient dies while waiting for a life-saving organ. Donor availability is one part of the equation... the other is time. XT-ViVo® & TimeSeal® will enable multi-day preservation and remove time from the equation. Read more --- - Published: 2023-11-15 - Modified: 2023-12-14 - URL: https://x-therma.com/news/advancing-treatment-for-type-1-diabetes-with-drs-camillo-ricordi-and-xiaoxi-wei/ Dr. Camillo Ricordi may be a familiar name to anyone who has, or has known someone, with type 1 diabetes. As director of the Diabetes Research Institute, Ricordi has spent his career studying the disease, which can be debilitating for patients, and which requires them to rely on daily insulin injections and glucose monitoring. In a recent episode of Cell & Gene: The Podcast, Dr. Ricordi sat down to discuss advances in the treatment of type 1 diabetes, as well as the challenges that persist and the current state of clinical research for the disease. Alongside X-Therma CEO Xiaoxi Wei, Ricordi also explored the limitations of traditional cryopreservation for both the pancreas itself and for islets of Langerhans, pancreatic cells that can be infused in portal veins within a patient’s liver, where they can become active and produce insulin. Finally, the pair talked about how advancements in cryopreservation technologies have the potential to pave the way for better, more accessible diabetes treatment. Read more --- - Published: 2023-09-01 - Modified: 2023-12-14 - URL: https://x-therma.com/news/the-future-of-dmso-free-and-serum-free-cryopreservation-for-advancedtherapies/ Cryopreservation is a crucial part of bioprocessing and biopharmaceutical manufacturing, storage, and transport – by using very low temperatures top reserve cells, cryopreservation can enable greater scale and access to life-saving therapies, grafts, tissues, and organs. As cell doses exponentially increase (~1 e9cells/dose), allogeneic cell banking returns to the forefront, and large-volume preservation (~500 mL) particularly for blood-based products become a necessity, cryopreservation continues to take the center stage. As it remains common to have sites of raw material collection, site of manufacture and site of clinical use to be different for any given product, one of the more significant challenges is in ensuring that these products retain their safety and efficacy through bioprocessing, storage, and transport. Cryopreservation is a complex undertaking, and one that requires a thorough understanding of the product’s critical quality attributes (CQAs) and the variables that may impact them. Though incumbent in the market for decades, more recent evaluations of the potential negative impacts of the industry’s primary cryopreservation solution, dimethyl sulfoxide (DMSO), on human health, alongside its incompatibility with processes in therapeutic cell production, have stimulated a push for alternative cryoprotectants. X-Therma, a company dedicated to pioneering cryopreservation solutions for organ transplant, tissue banking, and numerous advanced therapies including cell and gene therapy, focuses on using biomimicry to replicate the antifreeze properties of the natural antifreeze proteins (AFPs) found in some arctic species while retaining scalability and reproducibility. Read more --- - Published: 2023-08-23 - Modified: 2023-12-14 - URL: https://x-therma.com/news/science-chops-alone-dont-cut-it-the-entrepreneurial-growth-struggle/ In the eight years since launching X-Therma, we’ve achieved chemistry breakthroughs that we believe will truly propel the field of organ transplant to a new era. But learning hasn’t taken place solely in the lab; for me, the last eight years have been an education in entrepreneurship. It is the entrepreneurial struggle, this journey that scientists-turned-business owners must undertake. For many science and tech innovators, success or failure in entrepreneurship makes the difference between whether their ideas, however brilliant, end up changing the world or frozen forever as promising concepts in academic articles. The struggle is not something you learn in a PhD program. I’ve been a scientist, or a would-be one, all my life. As a kid I loved paleontology and dragged a dinosaur book everywhere I went; I also read about driverless cars and imagined futuristic worlds. I came from a small-town and it never entered my head that I could own a business even though I had 4 jobs in one summer — let alone start one that could help revolutionize an entire medical field. Profound opportunity put me on my path. One was that, after taking all science classes available, I discovered my abiding love for chemistry. Another was meeting Xiaoxi Wei in grad school at the State University of New York-Buffalo. Her brilliance in biotechnology and medicinal chemistry and her singular passion for improving the process of preserving organs for transplantation led directly to X-Therma and our quest to develop new molecules. I’ve never stopped... --- - Published: 2023-07-27 - Modified: 2023-12-14 - URL: https://x-therma.com/news/next-generation-cryopreservation-techniques-improving-cold-chain-management-for-regenerative-medicines/ Cryopreservation has become a crucial component in realizing the large-scale commercial manufacturing of regenerative medicines, which require unique storage and transport strategies to ensure their efficacy upon patient administration. The sensitivity of many of these fragile biotherapeutics make curtailing ice formation during freezing crucial; however, the toxicity and genomic damage associated with dimethyl sulfoxide (DMSO), the most commonly utilized cryoprotectant in the advanced therapy space, complicates the efforts to de-risk, standardize and scale production of these lifesaving treatments. Next-generation, DMSO-free, serum-free cryoprotectants may offer the answer to enabling more widespread regenerative medicine development and commercialization. A future in which regenerative medicines become accessible, off-the-shelf treatments for a range of rare and intractable diseases hinges, in part, on solving the challenges related to cold chain management for these therapeutics. By enabling safer cryopreservation with similar or greater efficacy than incumbent cryoprotectants, biopharmaceutical companies and manufacturers can realize a paradigm wherein these treatments can become a common recourse for millions of patients around the world. Read more --- - Published: 2023-06-26 - Modified: 2023-06-26 - URL: https://x-therma.com/news/x-therma-fcoi-policy/ X-Therma posts our FCOI to meet requirements of our incoming NIH funding. You can read the policy here: XT_FCOI --- - Published: 2023-05-24 - Modified: 2023-12-14 - URL: https://x-therma.com/news/next-generation-dmso-free-serum-free-cryopreservation-for-cell-and-gene-therapy-manufacturing-and-processing/ Listen in on this discussion about the latest developments in cryopreservation technologies and how they can revolutionize cell and gene therapy manufacturing, processing, and their implications for clinical implementation. Emphasis will be placed on novel DMSO-free and serum-free cryopreservation solutions and provide insights into how they can improve the quality and efficacy of raw materials, intermediates and final products in the cell and gene therapy space. The regenerative medicine field is rapidly advancing, with many pivotal trials underway. Particularly for large-scale commercialmanufacturing, cryopreservation is becoming a crucial component to ensure a longer shelf-life throughout production, resilient logisticsto transport, and ultimately maximum therapeutic efficacy during administration. However, the efficacy and yield of sensitive cell typessuch as induced pluripotent stem cells and genetically engineered cell-based immunotherapies are significantly limited due to iceformation and consequent damage, as well as genomic and in vivo toxicity associated with current cryoprotectants (e. g. , DMSO). Theseproblems further limit the realization of standard products in modern regenerative medicine as developed in allogeneic cell therapy andtissue engineering. Read more --- - Published: 2023-05-01 - Modified: 2023-12-14 - URL: https://x-therma.com/news/fixing-the-regenerative-medicine-supply-chain-2/ In the past few years, specifically through the COVID-19 pandemic, supply-chain vulnerabilities have become the topic of everyday conversation across all industries— not just among manufacturing CEOs but also everyone from consumers who had to wait months for a new washing machine to healthcare providers unable to keep certain drugs in stock. The pandemic and its global economic disruption made us all more aware of the magic of resilient logistics — and the sometimes stark consequences when they fail. Arguably, no industry is more dependent on an effective supply chain than regenerative medicine. According to the Alliance for Regenerative Medicine, there are currently almost 1,000 unique products in the pipeline, about 15% of which are in Phase III clinical trials; this is expected to triple in the next 3 years. To keep up with the demand, we need to shorten the timeline between discovery and clinical implementation, which is no easy feat. The speed at which these therapies are developing and the corresponding cycle time for manufacture raises a host of supply chain struggles, beginning with the need to acquire stable and high-quality raw materials. Companies also face labor challenges and the need for temperature-controlled distribution to ensure that final products are delivered in a safe and efficacious condition. But despite the tremendous potential and innovation inherent in these therapies, they larhttps://docsend. com/view/teifzv8ek4vecz7zgely still rely on cryopreservation techniques that are decades old. Read more --- - Published: 2023-04-18 - Modified: 2023-12-14 - URL: https://x-therma.com/news/next-generation-cryopreservation-to-help-advance-cell-and-gene-therapies/ The world has been waiting for the next scientific breakthrough incryopreservation. Dimethyl sulfoxide (DMSO), a by-product of the wood industry, has been in usesince 1953. It is one of the most studied pharmaceutical agents in the UnitedStates. Worldwide, more than 10,000 articles have been written on its medical andclinical implications. In practice, it penetrates the skin deeply and quickly withoutdamaging it. In the United States, DMSO has Food and Drug Administration(FDA) approval only for use as a preservative of organs for transplant (althoughunused) and for interstitial cystitis, a bladder disease. Doctors have prescribed itfor ailments which include treating pain, inflammation, arthritis, scleroderma andinterstitial cystitis. In the field of cryopreservation, DMSO is often used in 5 to 10% formulation along with HSA/FBS as a cryoprotectant agent for cells andtissues. In cell preservation specifically, cell functionality is greatly impaired by DMSO, as a multitude of studies show a low rate of cellsurvival after being thawed from the cryopreservation process. This challenge is often incredibly costly for scientific development andmanufacturing organizations — not only financially, but its significant role in disrupting the ability to complete the work. Due to theseconcerns over toxicity, side effects of its strong odor (comparable to the smell/taste of garlic) which can include vomiting, diarrhea andinjection site pain, it has fallen out of favor with the medical mainstream. Moreover, as a toxic and viscous liquid, DMSO requirespremium plastics to be used for safe handling, adding to the cost borne by laboratories. Read more --- - Published: 2023-04-05 - Modified: 2024-03-14 - URL: https://x-therma.com/news/xt-thrive-and-x-therma-next-generation-cryopreservation-to-help-advance-cell-and-gene-therapies/ The world has been waiting for the next scientific breakthrough in cryopreservation. Dimethyl sulfoxide (DMSO), a by-product of the wood industry, has been in use since 1953. It is one of the most studied pharmaceutical agents in the United States. Worldwide, more than 10,000 articles have been written on its medical and clinical implications. In practice, it penetrates the skin deeply and quickly without damaging it. In the United States, DMSO has Food and Drug Administration (FDA) approval only for use as a preservative of organs for transplant (although unused) and for interstitial cystitis, a bladder disease. Doctors have prescribed it for ailments which include treating pain, inflammation, arthritis, scleroderma and interstitial cystitis. In the field of cryopreservation, DMSO is often used in 5 to 10% formulation along with HSA/FBS as a cryoprotectant agent for cells and tissues. In cell preservation specifically, cell functionality is greatly impaired by DMSO, as a multitude of studies show a low rate of cell survival after being thawed from the cryopreservation process. This challenge is often incredibly costly for scientific development and manufacturing organizations — not only financially, but its significant role in disrupting the ability to complete the work. Due to these concerns over toxicity, side effects of its strong odor (comparable to the smell/taste of garlic) which can include vomiting, diarrhea and injection site pain, it has fallen out of favor with the medical mainstream. Moreover, as a toxic and viscous liquid, DMSO requires premium plastics to be used for safe handling,... --- - Published: 2023-03-21 - Modified: 2023-03-21 - URL: https://x-therma.com/news/x-therma-completes-nsf-program-with-flying-colors/ X-Therma is proud to announce an important milestone on our journey toward enabling more and better organ transplants and off-the-shelf regenerative medicine therapies: Our company is now officially a graduate of the National Science Foundation’s (NSF) Small Business Innovation Research (SBIR) program, having received funding and positive evaluations at all stages of the program. It’s a key moment in X-Therma’s evolution as a company because it signifies that, in the eyes of the NSF, we’ve moved beyond initial concept and research and development to market viability. The market has been confident in our future for some time, as we closed on an oversubscribed $13 million Series A funding round in December 2021. Still, we remain grateful for the early and consistent support from the NSF through what the agency calls “America’s Seed Fund. ” Inclusion in SBIR doesn’t just mean funding, although money to support research and development is crucial to the sort of early startup that X-Therma was in 2018. The NSF also gives guidance on the science and, critically, training for first-time entrepreneurs. Of the companies that submit proposals to SBIR, only 10% receive Phase I funding. From there about half make it to Phase II, which means more funding, plus more guidance on building a business to support your science. Companies at this stage undergo regular financial audits and must demonstrate viable business plans. A small number of Phase II participants qualify for a supplemental, Phase IIB round of funding — designed to accelerate commercialization of those... --- - Published: 2023-03-14 - Modified: 2024-10-02 - URL: https://x-therma.com/news/a-bioinspired-and-chemically-defined-alternative-to-dimethyl-sulfoxide-for-the-cryopreservation-of-human-hematopoietic-stem-cells/ The cryopreservation of hematopoietic cells using dimethyl sulfoxide (DMSO) and serum is a common procedure used in transplantation. However, DMSO has clinical and biological side effects due to its toxicity, and serum introduces variation and safety risks. Explore the development of a novel class of ice-interactive cryoprotectants inspired by natural antifreeze proteins. The cryopreservation of hematopoietic cells using dimethyl sulfoxide (DMSO) and serum is a common procedure used in transplantation. However, DMSO has clinical and biological side effects due to its toxicity, and serum introduces variation and safety risks. Explore the development of a novel class of ice-interactive cryoprotectants inspired by natural antifreeze proteins. XT-Thrive is identified as a lead candidate to rival cryopreservation with 10% DMSO in serum based on post-thaw cell survival and short-term proliferation assays. Herein, novel cryoprotectants were tested on hematopoietic cells. The fully synthetic cryoprotectants control ice formation and are non-toxic, chemically stable, and are protein-free. Candidate formulations were compared to 10% DMSO in serum for use during liquid nitrogen storage (−196 °C). Explore findings that show XT-Thrive can substitute the use of 10% DMSO and serum as a cryopreservation solution. Read more --- - Published: 2023-03-07 - Modified: 2023-12-14 - URL: https://x-therma.com/news/creating-time-how-emulating-nature-can-help-us-improve-outcomes-for-organ-transplant-patients/ I have spent my life thinking about time. How to pause it. How to create more of it. How to extend it, so that people might have longer, healthier, happier lives. It is the primary question I have pursued throughout my scientific career. It’s at the heart of the work I’ve done at the Lawrence Berkeley National Laboratory, and it is the reason I started X-Therma, a company developing a novel technology to increase the amount of time a cell or organ can be kept alive by using below-freezing temperatures: I want to give people more time. X-Therma’s technology is a chemically derived solution that mimics naturally occurring processes in plants and animals across the natural world, allowing cells and organs to survive at below-freezing temperatures. Our technology enables cells and organs to be frozen longer, preserving them for transplant, cell and gene therapies, and research. We’re creating time. The current modes of preservation come with a host of issues, chief among them is that they offer very short windows of time before cells and organs become unusable. Our technology not only emulates nature, it improves upon it — and tests conducted in our labs and by research partners around the world show incredible promise to hold organs at subzero temperature without ice. Read more --- - Published: 2023-03-03 - Modified: 2023-12-14 - URL: https://x-therma.com/news/taking-the-toxins-out-of-cell-therapy-storage-a-new-cryopreservation-molecule/ Inspired by nature, a new type of cryoprotectant has emerged as a safer alternativeto traditional chemicals. The preservation of living cells and tissues is an often-underappreciated obstacle inthe clinical lab. Cryogenic temperatures attempt to address this challenge byminimizing biochemical activity within samples of interest. As the cell and genetherapy market grows, the drawbacks of cryopreservation are becoming moreapparent. This article examines the current cryopreservation landscape within the cell andgene therapy market and explores emerging solutions to meeting supply demandsand patient safety standards. Read more --- - Published: 2023-01-19 - Modified: 2023-12-14 - URL: https://x-therma.com/news/novel-cryopreservation-for-cell-and-gene-therapies/ The concept of cooling organic materials in order to slow their decay is as old as civilization itself. For the preservation of food, it is as simple as freezing with ice to prevent bacterial or fungal growth; at worst, what occurs at both the tissue and cellular levels results in texture and consistency changes, altering the taste of what was frozen but not impacting its safety. Yet what occurs at the cellular level to cause this shift is ultimately highly destructive – the formation of ice crystals which can rupture and tear cells apart. This ice damage, while less concerning in food, is catastrophic for cell therapies. This requires freezing solutions to prevent ice formation, allowing for the retention of cells’ therapeutic functionality. For these modalities, as well as any tissue preserved for medical use, the need to preserve them in ways which allow them to revert to healthy cells after preservation has created complexity for the drug developers pursuing these therapies to treat rare and often intractable diseases. Read more --- - Published: 2023-01-13 - Modified: 2023-12-14 - URL: https://x-therma.com/news/next-generation-dmso-free-serum-free-cryopreservation-for-cell-and-gene-therapy/ Existing standards in cryopreservation use 5-10% dimethyl sulfoxide (DMSO) andoften serum. These products have not been significantly improved for over 50years. DMSO exhibits acute toxicity in patients and causes adverse cell mutation atlow levels (0. 1%) including irreversible cell chromosome damage and alterations inthe epigenetic landscape. Serum remains a black box, inherently introducingbatch-to-batch variability, diminished clinical reproducibility, and compromisedprecision in therapeutic delivery. However, performance in available DMSO &serum-free solutions is often compromised, warranting urgent advancement. Learn about XT-Thrive®, a completely defined, non-toxic cryopreservationsolution for cell & gene therapy and cell banking applications at ultra-lowtemperatures (-70°Cto-196°C). Formulated without any DMSO, serum, or recombinant proteins, every component is fully identified andquantified for superior compatibility with cGMP manufacturing processes. Read more --- - Published: 2023-01-11 - Modified: 2023-12-14 - URL: https://x-therma.com/news/chemically-defined-safe-and-effective-cryopreservation/ XT-Thrive® contains fully synthetic biomimetics (peptoids) which are non-toxic, and prevent harmful ice crystal formation in cells at temperatures down to-196°C. Under polarized light ice crystals reveal life saving secrets in a colorful wonderland. XT-Thrive® proprietary cryopreservation media is intended for cryopreservationof cell and gene therapies for regenerative medicine applications in ultra-low temperature environments (-70° C to -196° C). X-Therma offers Phase I GMP to full GMP grade XT-Thrive® and the product is manufactured with USP/highest quality components in a sterile environment with appropriate controls and testing. Full GMP Grade is in full compliance with FDA and EU Annex 1 current regulations and requirements. Learn more about the key benefits of this cryopreservation media, its field of applications and compatibility with large scale production, and its efficiency and safety in clinical environments. Read more --- - Published: 2022-12-22 - Modified: 2023-03-02 - URL: https://x-therma.com/news/a-wonderful-celebration-of-our-seventh-anniversary/ What a wonderful celebration of the 7th anniversary we had on Halloween weekend! We truly appreciate the commitment and contribution of our dedicated team and supportive members. We are a team with a bold dream, with incredible resilience and perseverance aiming for excellency while tirelessly pushing the boundaries of science. Thank you all, for your extraordinary support as we strive to make extraordinary changes to the path of humanity! Together, we create the future. Check out the video to see our future talks, future looks, and mesmerizing ice-cold Frankenstein: The heart is alive! --- - Published: 2022-12-20 - Modified: 2023-12-14 - URL: https://x-therma.com/news/reducing-adverse-events-and-improving-outcomes-during-and-after-cell-and-gene-therapy-with-dmso-free-non-toxic-cryopreservation/ Cryopreservation for cell and gene therapies has long been a crucial consideration for drug developers and manufacturers. These modalities require unique formulation approaches in order to preserve their therapeutic properties at every processing step, from isolation, expansion and fill/finish to storage, transport, and administration. Despite the value of these biologics and the innovations surrounding their therapeutic potential, the cryopreservation techniques that typify these treatment shave remained largely unchanged in several decades. The cryoprotectant dimethylsulfoxide (DMSO) remains the incumbent method for regulating ice formation during the freezing process, in spite of its relative toxicity and documented propensity for inducing irreversible chromosomal and other intracellular damage. These concerns exist alongside growing recognition from the industry that DMSO can also serve to limit pre-freeze and post-thaw incubation times, creating the potential for processing bottlenecks and product loss. Read more --- - Published: 2022-11-11 - Modified: 2023-02-24 - URL: https://x-therma.com/news/from-arctic-fish-to-new-cell-therapy-preservation-technologies/ Cryopreservation should maintain the function and viability of organs and cell therapies, but the process is riddled with challenges. Can nature-inspired proteins make a difference? --- - Published: 2022-06-20 - Modified: 2022-12-30 - URL: https://x-therma.com/news/improving-health-equity-through-worldwide-organ-sharing/ The organ transplantation field has experienced numerous barriers which have contributed to the creation of organ accessibility issues worldwide. To help tackle these challenges, X-Therma has made it its mission to make worldwide organ sharing possible for everyone, eliminate organ waiting lists across the globe and improve lives. --- - Published: 2022-05-09 - Modified: 2022-12-30 - URL: https://x-therma.com/news/emerging-therapies-face-development-hurdles/ While traditional biologics continue to see strong market demand, the need for emerging therapies, such as regenerative medicines, has also given rise to a burgeoning pipeline. The biopharmaceutical industry has seen significant levels of investment going into clinical-stage projects for cell therapies, gene therapies, and other regenerative medicines over the past year (1) as efforts increase to tackle the development and manufacturing hurdles for these therapies. --- - Published: 2022-05-03 - Modified: 2023-01-03 - URL: https://x-therma.com/news/therma-receives-fda-breakthrough-device-designation-for-xt-vivo-preservation-solution-and-timeseal-organ-transport-device/ X-Therma Inc. , a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation – announced today that The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has granted its proprietary organ preservation solution, XT-ViVo®, and TimeSeal® Organ Transport Device, Breakthrough Device status. This designation is granted to products that have the potential to offer more effective diagnosis or treatment of life-threatening diseases with an unmet medical need. “This milestone moves us as a company, and more broadly as an industry, one step closer to tackling the organ shortage problem,” says Dr. Xiaoxi Wei, CEO & Co-Founder of X-Therma. “With less than 10 percent of the worldwide demand met for transplantable organs, being able to remove time barriers for safe and reliable organ preservation, without changing the peri-transplant workflow, is a game-changer and, we envision, will prove to be a lifesaver for all of those in need. ” XT-ViVo® is a novel organ preservation solution indicated for perfusion and flushing of a donor’s kidney prior to removal from the donor or immediately after removal from the donor. The solution is left in the organ vasculature during hypothermic storage and transportation to the recipient. TimeSeal® Organ Transport Device is designed for static hypothermic preservation of adult donor kidneys during transportation and subsequent transplantation into a recipient using XT-ViVo®. The anticipated debut of this device into the market has the potential to provide extended organ storage time for up to 120 hours. Donor kidneys that... --- - Published: 2022-04-28 - Modified: 2022-12-30 - URL: https://x-therma.com/news/x-therma-brings-biomimetics-to-bioprocessing/ In the past two years, the cold chain turned into one of the most talked-about aspects of healthcare. Biotechnology company X-Therma in Richmond, CA, plans to improve the cold steps in the bioprocessing of cell and gene therapies with biomimetics. --- - Published: 2022-04-11 - Modified: 2023-12-14 - URL: https://x-therma.com/news/preserving-cell-and-gene-therapies-without-using-toxins/ Every day it seems you can find a headline somewhere describing the extraordinary progress scientists have made in developing cell and gene therapies for rare genetic diseases, a variety of cancers, and common ailments that affect most of the industrialized world. Genetic material is now common in vaccines, too, as scientists discovered that mRNA is an effective starting point for eliciting a strong immune response to SARS-COV-2. But besides their genetic components, all these medical products face a common challenge: they must be kept cold during storage and transport to remain viable until they can be used. Unfortunately, current techniques for cryopreserving cells and tissues are not built to preserve medical products. But today, scientists and engineers are developing new tools such as protein-like “peptoids” that can make cold storage and transport easier, safer and more reliable. --- - Published: 2022-04-07 - Modified: 2022-12-30 - URL: https://x-therma.com/news/article-discover-magazine-the-people-making-organ-transplants-more-efficient/ Existing and emerging biotech advances are transforming the way we preserve and transport donated organs. While their methods may vary, all share a common end goal: saving more lives. --- - Published: 2022-03-23 - Modified: 2023-03-02 - URL: https://x-therma.com/news/the-next-generation-of-cryopreservation-technology/ Living cells, tissues, and organs are more critical to medicine than ever before, but current cryopreservation techniques are not enough to keep these materials viable during storage and transport. Peptoids may provide the solution. --- - Published: 2021-12-22 - Modified: 2022-12-30 - URL: https://x-therma.com/news/x-therma-announces-oversubscribed-series-a-financing/ RICHMOND, Calif. — December 22, 2021 — 6:00 AM PT — X-Therma Inc. , a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation – has closed an oversubscribed $13M Series A funding round. The financing is led by LOREA AG, an entrepreneur-operated investment firm, with participation from Zen11 Holdings, Graphene Ventures, VU Venture Partners, 2b AHEAD Ventures, Methuselah Foundation, Catalytic Impact Foundation, along with notable return angel investors. X-Therma’s technology, a nontoxic biopreservation platform enabled by biomimetic peptoid, is transforming global accessibility to organ transplantation, as well as enabling “off-the-shelf” cell and gene therapy products and engineered tissues by providing safe & effective chemically defined cryopreservation that is DMSO-, serum-, and protein-free. More and Better Organ Transplants “We’re excited about the transformative impact of X-Therma’s technology and potential to better meet society’s demands of safely and successfully transplanting organs across the globe,” says Dr. Christoph Swarovski, owner and founder of LOREA AG. “Our conviction in this technology was inspired by the world’s dire need of a better solution for organ transport and we are fortunate to help X-Therma bring its vision to fruition. ” X-Therma has made a quantum leap in demonstrating a significant extension of organ shelf-life from a few hours to a few days in collaboration with world-leading surgeon, Dr. Gerald Brandacher at Johns Hopkins University. Less than 10% of the worldwide demand for transplantable organs is being met. Despite many improvements in surgical techniques and immunosuppression, innovations to extend the time window for safe... --- - Published: 2021-07-01 - Modified: 2022-12-30 - URL: https://x-therma.com/news/new-published-article-in-bone-marrow-transplantation/ What a great way to wrap up our collaborative work with Vitalant Research Institute, Marcus Muench, Philip Norris in Bone Marrow Transplantation, a Nature Journal! Looking for DMSO- and Serum-free alternative cryopreservation media that is process friendly, safe to use, and does not compromise the performance? The wait may be over with XT-Thrive®. We look forward to further supporting your research, GMP cell production and clinical need! #Celltherapy #GeneTherapy #bonemarrowtransplantation --- - Published: 2021-06-07 - Modified: 2022-12-30 - URL: https://x-therma.com/news/join-for-the-excitement-of-pushing-boundaries-in-organ-preservation/ “Is it possible to achieve successful VCA transplantation after 72hrs ischemia at sub-zero temperature? ” @X-Therma is pleased to get the answer revealed during the highly competitive Rapid Fire Oral Abstract session at American Transplant Congress #ATC2021 at 6PM EST on Tuesday, June 8. Dr. Samuel Fidder @Samuel Fidder (https://lnkd. in/eKxh_wz) of @Johns Hopkins University will present our joint work and answer your questions live. Join for the excitement of pushing boundaries in organ preservation with translational ready procedures powered by fundamental chemistry breakthroughs! --- - Published: 2021-06-01 - Modified: 2022-12-28 - URL: https://x-therma.com/news/jim-greenwood-and-robin-farmanfarmaian-join-x-therma-advisory-board/ Chairman, BVGH Board of Directors; President & CEO, Biotechnology Innovation Organization (2005 – 2020) Jim is the outgoing President & CEO of the Biotechnology Innovation Organization (BIO) in Washington, D. C. BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial, and environmental biotechnology products. Jim represented Pennsylvania’s Eighth District in the U. S. House of Representatives from 1993 through 2004. As a leader on healthcare issues, he authored numerous bills signed into law, including legislation to promote pediatric labeling for pharmaceuticals, reform medical device review and approval, and expand research and establish innovative programs to address traumatic brain injury. His legislation to reform medical liability insurance passed the House several times but stalled in the Senate. From 2001 to 2004, Jim served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over all issues in the full Committee’s vast jurisdiction. He held hearings on topics ranging from bioterrorism to corporate governance to the safety of nuclear power plants. Prior to his election to Congress, Jim served six years in the Pennsylvania General Assembly (1980-86) and six years in the Pennsylvania Senate (1986-1993). He specialized in health, environment, and children’s issues. Jim graduated from Dickinson College in 1973 with a BA in Social Work. From 1977 until 1980, he worked as a social worker with abused and... --- - Published: 2021-05-18 - Modified: 2022-12-30 - URL: https://x-therma.com/news/we-are-honored-to-be-featured-in-the-may-issue-of-aiche/ We are honored to be featured in the May Issue of AIChE – American Institute of Chemical Engineers. Special thank you to the National Science Foundation National Science Foundation (NSF) for instrumental and continuous support. Debuting disruptive science is never easy, but we are lucky to have a dedicated team with the drive to make the impossible possible and continuously push the boundaries in science. Come join us to make the world a better place! No more waiting in vain! --- - Published: 2020-12-23 - Modified: 2022-12-28 - URL: https://x-therma.com/news/x-therma-is-awarded-for-nsf-grant-continuously/ X-Therma was supported early on by the National Science Foundation (NSF) to develop ice-interactive biomimetic nanomaterial to advance biopreservation for unmet needs in Regenerative Medicine. We have advanced from R&D to development through Phase I and Phase II funding. Now, we are very excited to enter the Phase IIB stage to commercialize our product for tissue preservation with exclusive support from NSF. We would like to thank AlloSource® and their Innovation Center as our partner on this exciting journey, making on-demand tissue available for patients in need. --- - Published: 2020-10-01 - Modified: 2023-03-02 - URL: https://x-therma.com/news/organ-missing-in-transit-shall-be-preventable/ Sad but true. It’s astonishing to see the number of lives impacted. “In a nation where nearly 113,000 people are waiting for transplants, scores of organs – mostly kidneys – are discarded after they don’t reach their destination in time. ” Facts like this are what motivate us to drive real change. X-Therma’s solution safely preserves organs longer thus expanding the time available for transit, making problems like this one preventable. --- - Published: 2019-12-31 - Modified: 2022-12-28 - URL: https://x-therma.com/news/x-therma-is-one-of-the-winners-of-the-2019-nanoart-image-contest/ X-Therma competed at the Molecular Foundry’s NanoArt Image Contest. The contest is held annually, to celebrate the National Nano Day. “National Nano Day is an annual celebration on 10/9 to help raise awareness of nanotechnology, how it is used in products that enrich our daily lives, and the challenges and opportunities it holds for the future. “ Under polarized light, ice crystals reveals life saving secrets in a colorful wonderland. A story of “Nice Ice” enables life to thrive in a frozen world. (Top) water freezes into large hexagonal ice crystals; (Bottom) Antifreeze protein from arctic fish alters the ice crystals into dual pyramid shape. (Middle) Nature-inspired, Ice-interactive peptoid XT-ViVo shapes smaller, rounder and safer ice than Nature. The XT-ViVo peptoid has been used to preserve murine hearts below 0C for greatly extended time periods and return back to life for successful transplants. Further application in human organ transplant will help end the organ transplant wait list and save millions of lives. The image was taken at the Biological Nanostructures Facility on the Nikon Optiphot-POL polarized microscope w/ X-Therma Cryostage by Xiaoxi Wei, X-Therma Inc. , including assistance by Mark Kline, Adam Childs, Mussie Gide, and Andrea Callegari. --- - Published: 2019-09-19 - Modified: 2023-03-02 - URL: https://x-therma.com/news/x-therma-selected-as-buzz-of-bio-winner/ X-Therma has been selected as a Buzz of Bio winner in the category Diagnostics and Beyond! Thanks to everyone who voted for us and bringing organ banking closer to the hundreds of thousands of patients that need it today. Buzz of BIO is a contest that recognizes U. S. based companies with groundbreaking, early stage technologies with the potential for improving our lives. The BIO Investor Forum takes place on October 22-23 in San Francisco, CA. --- - Published: 2019-03-10 - Modified: 2022-12-28 - URL: https://x-therma.com/news/x-therma-was-awarded-the-global-health-prize-from-bayer/ “Throughout the year, Hello Tomorrow partners with top universities, research labs, accelerators and incubators around the globe to find entrepreneurs at a very early-stage who are developing new scientific and technological solutions. This year, the Global Challenge saw a record of 4,500 applications from 119 countries, indicating that the development of new technologies is more widespread than ever before. --- - Published: 2018-09-30 - Modified: 2022-12-30 - URL: https://x-therma.com/news/first-place-in-svief-star-final-silicon-valley/ X-Therma Inc. received 1st place in the fierce top 15 competition to win the 2018 annual SVIEF Star Award. X-Therma Inc. received 1st place in the fierce top 15 competition to win the 2018 annual SVIEF Star Award. Hundreds of companies competed throughout the recent month and 10,000 investors, entrepreneurs, and Silicon Valley community attended the event. We turn your Sci-Fi dream into reality with XT-ViVo. --- - Published: 2018-09-21 - Modified: 2022-12-30 - URL: https://x-therma.com/news/second-place-of-mtec-final-qingdao/ X-Therma Inc. received 2nd place for the 2018 International Marine Innovation and Entrepreneurship Competition in Qingdao, China for XT-ViVo, the ocean-inspired nanoscience breakthrough to revolutionize the cold chain of regenerative medicine. --- - Published: 2018-02-28 - Modified: 2022-12-30 - URL: https://x-therma.com/news/confidence-xt-vivotm/ X-Therma CEO Dr. Xiaoxi Wei welcomed her first baby into the world and is proud he became the first donor and “Patient” for X-Therma CORDX program. X-Therma CEO Dr. Xiaoxi Wei welcomed her first baby into the world and is proud he became the first donor and “Patient” for X-Therma CORDX program. The medical team at Kaiser Permanente Oakland Medical Center collected the cord blood, cord tissue and placenta from the newborn with X-Therma’s collection kit. The precious cord and placental stem cells and tissues were seamlessly delivered to X-Therma’s facility in Richmond and cryopreserved with the XT-ViVoTM products series in liquid nitrogen (-196℃) following GMP standard practices. The future revival of such stem cells and tissues will benefit from non-toxic XT-ViVoTM solutions with excellent recovery from freezing. X-Therma continues to advance the hope for effective regenerative medicine treatments. --- - Published: 2017-06-14 - Modified: 2022-12-28 - URL: https://x-therma.com/news/x-therma-selected-california-institute-regenerative-medicine-cirm-highly-competitive-funding/ X-Therma is selected by the California Institute of Regenerative Medicine (CIRM) for highly competitive funding to fuel X-Therma’s development to advance critical stem cell manufacturing processes. --- - Published: 2017-06-13 - Modified: 2022-12-28 - URL: https://x-therma.com/news/x-therma-competitively-selected-third-us-department-army-sbir-phase-ii-sbir-contract/ X-Therma is competitively selected for a third US Department of the Army SBIR Phase II SBIR contract. X-Therma’s CryomatrixTM is a new pipeline of non-toxic and hyper-effective cryoprotectants in development for cell, tissue, and organ banking. --- - Published: 2017-06-05 - Modified: 2022-12-30 - URL: https://x-therma.com/news/x-therma-ceo-dr-xiaoxi-weis-career-development-story-featured-chemical-engineering-news/ X-Therma CEO Dr. Xiaoxi Wei’s career development story is featured in Chemical &Engineering News (C&EN, Volume 95 Issue 23 | p. 23| Issue Date: June 5, 2017). An enlightening story of her inspiration to start the startup journey guided by a childhood dream. --- - Published: 2017-04-28 - Modified: 2022-12-28 - URL: https://x-therma.com/news/x-therma-competitively-selected-second-us-department-defense-phase-ii-sbir-contract/ X-Therma is competitively selected for a second US Department of Defense Phase II SBIR contract. This contract funds genitourinary organ transplants performed with XT-ViVoTM cryopreserved tissue. --- - Published: 2016-10-10 - Modified: 2022-12-28 - URL: https://x-therma.com/news/x-therma-featured-wirtschaftswoche-top-weekly-magazine-german-economy/ X-Therma is featured in “Wirtschaftswoche“ – top weekly magazine in German Economy. —59 Valley Talk: Investoren begeistern sich für Transplantationstechnik, WirtschaftsWoche Ausgabe 42/2016 --- - Published: 2016-06-18 - Modified: 2022-12-30 - URL: https://x-therma.com/news/future-talk-2b-ahead-congress-germany/ Future talk at 2b AHEAD Congress 2016 in Germany – Our CEO Xiaoxi Wei shared our future vision on saving lives and building a greener Earth by advancing anti-Ice technology! --- - Published: 2016-05-05 - Modified: 2022-12-28 - URL: https://x-therma.com/news/x-therma-is-competitively-selected-by-for-a-us-department-of-defense-phase-ii-sbir-contract/ X-Therma is competitively selected by for a US Department of Defense Phase II SBIR contract. Murine heart transplants will be performed with XT-ViVoTM cryo X-Therma is competitively selected by for a US Department of Defense Phase II SBIR contract. Murine heart transplants will be performed with XT-ViVoTM cryo --- - Published: 2015-11-23 - Modified: 2022-12-30 - URL: https://x-therma.com/news/x-therma-inc-won/ Congratulations to X-Therma Inc. for the Patrick Soon-Shiong Innovation Award 2015 hosted by the Los Angeles Business Journal! Congratulations to X-Therma Inc. for the Patrick Soon-Shiong Innovation Award 2015 hosted by the Los Angeles Business Journal! This award is for our dedication and advancement toward non-toxic hyper effective bio inspired nano-material to fight ice, which will revolutionize >$200 Billion Global Market, and benefit millions of lives. X-Therma Inc. is also featured on the Molecular Foundry’s homepage for this. --- - Published: 2015-06-02 - Modified: 2022-12-30 - URL: https://x-therma.com/news/x-therma-atomic-precision-medical-application-workshop-hosted-foresight-institute/ Fun debut at the Atomic precision for medical application workshop hosted by Foresight institute. Fun debut at the Atomic precision for medical application workshop hosted by Foresight institute. Our Cancer target proposal “G-Can” won the highest votes from NanoScience experts with $ 920,000,000 virtual investment! Congrats to our TEAM: Kevin Perrott Dr. Mark Kline Dr. Xiaoxi Wei Dr. Stephanie Malone Prof. Anne-Sophie Duwez Prof. Jennifer Dionne Alice Lay Yang Zhao On the deal table with one of our investors – 2014 Feynman award winner Dr. Joseph W. Lyding --- - Published: 2015-05-28 - Modified: 2022-12-28 - URL: https://x-therma.com/news/x-therma-granted-u-s-department-defense-phase-research/ X-Therma is granted by U.S. Department of Defense for Phase I research on developing breakthrough cryoprotective agents (CPAs) for large organ/tissue cryopreservation! X-Therma is granted by U. S. Department of Defense for Phase I research on developing breakthrough cryoprotective agents (CPAs) for large organ/tissue cryopreservation! --- --- ## White Papers --- ## Jobs ---